GSNOR Inhibitor

N6022 is a potent, selective, reversible, and efficacious S-Nitrosoglutathione reductase(GSNOR) inhibitor with IC₅₀ of 8 nM.

Cavosonstat (N91115) is an orally active S-nitrosoglutathione reductase (GSNOR) inhibitor. Cavosonstat is a CFTR stabilizer, and can be used for cystic fibrosis research.

SPL-334 is a potent and selective S-Nitrosoglutathione reductase (GSNOR) inhibitor. SPL-334 causes a significant reduction in the production of Th2 cytokines IL-5 and IL-13 and the levels of the chemokine CCL11 (eotaxin-1) in the airways. SPL-334 can be used in research of allergic airway inflammation.

GSNOR-IN-1, a prodrug of GSNOR-IN-2 (HY-176275), is a BBB-penetrable S-nitrosoglutathione reductase (GSNOR) inhibitor. GSNOR-IN-1 has significant protective activity against OGD/R-induced injury. GSNOR-IN-1 regulates calcium signaling and synaptic function via Clstn1 S-nitrosation and inhibits neuronal apoptosis. GSNOR-IN-1 significantly reduces infarct volume while improving neurological deficits in ischemic stroke rat models. GSNOR-IN-1 has neuroprotective activity, promising for ischemic stroke research.

GSNOR-IN-2 (Compound 45) is a S-nitrosoglutathione reductase (GSNOR) inhibitor with an IC₅₀ of 44.12 nM. GSNOR-IN-2 has neuroprotective activity, promising for ischemic stroke research.

Cavosonstat (Standard) is the analytical standard of Cavosonstat (HY-109027). This product is intended for research and analytical applications. Cavosonstat (N91115) is an orally active S-nitrosoglutathione reductase (GSNOR) inhibitor. Cavosonstat is a CFTR stabilizer, and can be used for cystic fibrosis research.

N6022 (Standard) is the analytical standard of N6022. This product is intended for research and analytical applications. N6022 is a potent, selective, reversible, and efficacious S-Nitrosoglutathione reductase(GSNOR) inhibitor with IC50 of 8 nM.